Selected by 6 outstanding medical researchers from around the world… 1 million dollars (approximately 1.1 billion won) support for 3 years ㆍResearch on new drug development for macular degeneration
▲ Lee Jun-yup, professor of ophthalmology (photo provided by Asan Medical Center, Seoul)
Seoul Asan Hospital announced on the 10th that Ophthalmology Professor Jun-yup Lee was selected for the’Novatis Global Innovation Research Support Program’.
The global innovation research support program, first launched by the Institute of Biomedical Research (NIBR) of Novartis, a global pharmaceutical company, comprehensively evaluates the competency of the research institute and the proposals of the researchers among excellent researchers around the world, and 6 out of 700 applicants. Was selected.
Novartis has qualified researchers from just 38 institutions in nine countries around the world to apply for research support programs among medical research institutions with excellent research capabilities in each country. Only two were included in the support, including five in Asia and Seoul Asan Hospital in Korea.
Lee Jun-yeop, a professor of ophthalmology at Seoul Asan Medical Center, will receive 1 million dollars (approximately 1.1 billion won) for three years from this year to 2023 to conduct research on the development of a new drug for macular degeneration without a fundamental treatment.
Lee Jun-yeop, a professor of ophthalmology at Seoul Asan Hospital, said, “Since there is no effective preventive or fundamental treatment for macular degeneration, we had to slow the progression and manage our eyesight through the use of nutritional supplements or intraocular injection therapy.” “We will develop a new drug that can fundamentally treat macular degeneration through a joint research with the ophthalmologist at Asan Medical Center through the Novartis Global Innovation Research Support Program selected on the basis of.”